Explore the Agenda
7:45 am Check In & Morning Coffee
8:45 am Chair’s Opening Remarks
Unlocking the Discovery, Development & Outlook of The Peptide Therapeutics Industry Through Leadership Perspectives
8:50 am An Outlook on Peptides: 2026 & Beyond
9:00 am The Infinite Loop: Machine Learning for Discovery, Delivery & Rapid Manufacturing of Potential Medicines
- We’re facing a challenge in the world of chemistry: Our lack of data is slowing down how we can use clever computer programs, known as machine learning, to create powerful new medicines
- Creating data highways from millions of small molecules, peptides and small proteins
- Using machine learning to discover and create new functional molecules quickly. Sometimes, these computer-designed molecules are even better than what we can make ourselves
- Developing an infinite loop where we automatically design, build, and test potential new medicines
9:30 am Peptide Industry Leaders’ Discussion – Unlocking Next Frontiers of Bioavailable Peptide-Based Therapeutics to Patients Faster
This your chance to hear from pioneering executive leaders the peptide space who will discuss their ambitions, strategies and challenges for peptide discovery, targets. indications and development of next generation of peptide drugs.
Key questions to be addressed include:
- What are the future opportunities, promising targets and applications on the horizon for peptide-drugs to achieve the next best in-market approval?
- Where is the next big wave heading after GLP-1 peptides?
- How will peptide-drugs compete against the biologics, antibody and small molecule markets as standards of care?
10:30 am Morning Break & Speed Networking
This informal session provides the perfect opportunity to connect with industry frontrunners and key opinion leaders in the peptide-based therapeutics field. Get ready to engage with 100+ key stakeholders, swap your business cards and establish meaningful connections to build upon at the rest of the conference.
Track A: Drug Discovery
Pioneering the Potential of Cutting-Edge Computational Chemistry Approaches & Discovery Platforms to Enable Superior Peptide Breakthroughs
11:30 am Computational Detail of Drug Discovery & Platform Technology Development for Cyclic Peptides
- Advancing hit-to-lead methods specialized for peptides
- Showcasing the formalization of drug-likeness criteria for orally available peptides
- Demonstrating the role of computer chemistry for platform technology development
NEW DATA
12:00 pm Peptide Drug Hunting: Innovative Science & Technology Empowering Breakthrough Medicines
- Unveiling recent milestones in peptide drug discovery
- Boosting innovative R&D platforms from design to delivery
- Looking into the future challenges and opportunities
Track B: Formulation & CMC
Delivering Orally Bioavailable Peptides with Increased Stability & Half-Life Through Formulation Innovation
11:30 am Advancements & Challenges in Oral Peptide Delivery
- Highlighting the challenges in oral delivery
- Presenting solutions on how to overcome these challenges with focus on using high throughput screening approaches
- Demonstrating case studies examples of increasing oral exposure in dogs using next generation formulations
12:00 pm Translating the Oral Formulation of Peptides with Permeation Enhancers
- Reviewing the mechanisms of action of key intestinal permeation enhancers
- Spotlighting clinical development of oral peptide formulations with enhancers
- Re-purposing known excipients as permeation enhancers for oral peptide administration
12:30 pm Lunch Break & Networking
Track A: Drug Discovery
Showcasing the Advances & Clinical Progress of Peptide-Based Therapeutics to Combat Cancer Indications
1:30 pm A Clinical Update on ST316 & Lucicebtide, First-In- Class Peptide Antagonists of β-catenin/BCL9 and C/EBPβ, in Colorectal Cancer & Glioblastoma
- Presenting a clinical update on ST316, including the latest data from ongoing Phase 2 clinical program in colorectal cancer
- Spotlighting a clinical update on lucicebtide, including latest data update from Phase 2 clinical program in glioblastoma
NEW DATA
2:00 pm Discovery of Orally Bioavailable First-in-Class Cyclin A/B RxL Inhibitors to Treat Cancers with High E2F Activity
- Previously we’ve disclosed passive permeable macrocyclic peptides that bind to the HP of both Cyclin A and B to induce potent and selective apoptosis of E2F high cancer cells. However, their oral bioavailability was insufficient to advance to pre-clinical development
- Discussing the optimization of this scaffold for drug-like properties and oral bioavailability, resulting in a new scaffold with improved ADME properties and demonstrating tumor regression in CDX models of small-cell lung cancer via oral dosing
- This compound is a close analog of our lead compound CID- 078, currently being investigated in a Ph.1 trial for patients with SCLC, TNBC, or solid tumors harboring RB1 mutation, sharing similar characteristics and allowing us to show how we optimized properties within the series
NEW DATA
2:30 pm Opportunity For Sponsorship
Enquire with us at [email protected]
Track B: Formulation & CMC
Unravelling Strategies to Maximise Peptide Bioavailability Across Cell Types & With Extended-Release Mechanisms
1:30 pm Oral Formulations for Macrocyclic Peptides & Linear GLP-1 Peptides
- Highlighting the impact of gastrointestinal targeting
- Improving oral bioavailability across the gut
- Strategies to reduce negative food impact
NEW COMPANY
2:00 pm Polymeric Extended Peptide Drug Delivery Platforms for Improving Bioavailability
- Showcasing polymeric microparticles for extended release
- Highlighting post treatment for improving controlled release profiles
- Identifying the gaps between in vitro and in vivo systems
NEW COMPANY
2:30 pm Session Reserved For CPC Scientific
2:40 pm Afternoon Networking Break & Scientific Poster Session
The scientific poster session is your prime time to share your work with peers from across peptide-specific disciplines to advance therapeutic progress using a diversity of approaches across discovery and development whilst forging potential collaborations. Submit your abstract here. Submission deadline is April 10.
Harnessing the Best & Most Advanced Drug Delivery Systems & Routes of Administration for Successful Peptide Targeting Across Diseases
3:30 pm Fireside Peptide Delivery Discussion – Pushing the Limits of Peptide Formulation & Delivery from Novel Design to Effective Targeting Strategies for Better Patient Outcomes
- How to effectively design patient-centric peptide delivery formulations (oral vs injectable)?
- How to ensure novel peptide formulations can be scalable and cost efficient during the manufacturing process?
- Where will delivery innovations take the peptide field in the next 5 years?
4:15 pm Breaking Barriers – Redefining Oral Peptide Drug Delivery
More information coming soon.